ArticleAACE endocrinology and diabetes
Pathogenic HNF1A Variant in an Indonesian Family: Atypical Management of MODY3 Guided by Patient Comorbidity.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hyperglycemia Due to HNF1A-Mutation-Associated Maturity-Onset Diabetes of the Young (MODY) in a 6-Year-Old Kazakh Girl.The American journal of case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Maturity-onset diabetes of the young (MODY) is an autosomal dominant form of monogenic diabetes frequently misdiagnosed as type 1 or type 2 diabetes. Identifying the specific subtype is crucial, as several subtypes, such as Case Report: A 19-year-old male with a history of diabetes presented with right-sided weakness, aphasia, and facial asymmetry. He was admitted for gamma knife radiosurgery to treat a left basal ganglia arteriovenous malformation. One month prior to this admission, he had undergone surgical evacuation of an intracranial hemorrhage-a complication of his arteriovenous malformation-at another hospital. He was discharged on a basal-bolus insulin regimen due to hyperglycemia during that hospitalization and was subsequently referred to our center. During the current admission, glycemic control was achieved, allowing gradual reduction of insulin dose and transition to oral sitagliptin/metformin XR upon discharge. Genetic testing later confirmed a pathogenic c.160C>T variant in the Discussion: Although sulfonylureas are typically the first-line treatment for Conclusion: This case underscores that while genetic confirmation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.